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To the Editor,
Apple and Jaffe [1] recently reported on an adjustment 
to the high-sensitivity cardiac troponin T (hs-TnT) assay 
and questioned the consequent clinical implications. We 
report further on the effect of restandardisation of the 
assay on diagnostic performance. In our study between 
November 2008 and February 2011 (Trial registration 
ACTRN12610000053022) the diagnostic accuracy of the 
hs-TnT assay for acute myocardial infarction (AMI) was 
determined in a well-characterised but unselected cohort 
of patients presenting to the emergency department with 
chest pain suggestive of acute coronary syndrome (ACS) 
in whom blood was drawn for assay at presentation and 
after 2  h [2]. Serum was stored at −80°C for later cTnT 
analysis in 2012 using the Roche cobas e601 hs-TnT assay 
(Roche Diagnostics, Sydney, Australia; reagent lot no. 
00163704; calibrator lot no. 00165094). Clinical endpoint 
adjudication was performed by one of two cardiologists 
using all clinical information available up to at least 
30  days following presentation including results of the 
hospital’s usual troponin assay performed at presenta-
tion and after 6–8  h (Beckman Coulter AccuTnI, deci-
sion cut-off 40 ng/L cTnI). The outcome for the analysis 
of diagnostic accuracy was AMI at presentation and was 
diagnosed according to the Universal Definition of Myo-
cardial Infarction published at the time of adjudication 
[3]. Briefly, this was defined as evidence of myocardial 
necrosis together with clinical evidence of myocar-
dial ischaemia (ischaemic symptoms, ECG changes, 
or imaging evidence). Necrosis was diagnosed on the 
basis of a rising or falling pattern of the laboratory cTnI 
concentrations, with at least one value above the 99th 
percentile.
Following completion of the hs-TnT analysis in 
2012 a technical bulletin (No: 12–023) was published 
by Roche Diagnostics (Penzberg, Germany) calling 
for adjustment to the calibration of the hs-TnT assay 
when performed with certain reagent lots [1]. All study 
samples were found to require adjustment. This was 
performed according to the manufacturer’s method in 
which a new value assignment of the calibrator set used 
in this study was required. The result was that following 
recalibration the number of values that were below the 
limit of detection (5 ng/L) decreased from 1178 (71.0%) to 
560 (33.8%). Eighty-six of 1659 values were in the cTnT 
concentration range 8.71–13.94 ng/L, and when recalcu-
lated were on average 5 ng/L above the decision cut-off 
of 14 ng/L in the range 14.04–18.93 ng/L. The difference 
between recalculated and original values was +38% at 
the decision limit of 14 ng/L compared with +15.3% at 30 
ng/L cTnT (Figure 1).
Seven hundred and thirty-seven patients were 
included in the clinical analysis and an adjudicated 
diagnosis of AMI at presentation was made in 50 (6.8%) 
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individuals. Troponin T was elevated at either baseline 
or after 2 h in 168 (22.8%). The effect of recalibration on 
the diagnostic performance of the hs-TnT assay was to 
increase diagnostic sensitivity from 94.0% to 96.0% and 
negative-predictive value from 99.5% to 99.6%, and to 
decrease diagnostic specificity from 88.2% to 82.5% and 
positive-predictive value from 36.7% to 28.6%.
In order for laboratory troponin measurements to 
be reliable for patient management, measurement per-
formance (i.e., bias, imprecision, total error) should fall 
within clinically relevant limits. The definition of accept-
able performance for cTnI and cTnT measurements is still 
under discussion, but the biological variability data can 
help in objectively defining the allowable goals. A total 
CV  < 10% and an assay bias within  ± 15% may represent a 
good compromise for minimum analytical requirements 
and is consistent with a minimum total error goal of ~33% 
at the 99th percentile reference limit [4]. The observed 
bias in this study of −38% at 14 ngL cTnT for the hs-TnT 
assay exceeded this goal and a reassignment of hs-TnT 
calibrators was required to regain traceability to the man-
ufacturer’s master calibrator.
In this study the assay recalibration had only a modest 
effect on diagnostic accuracy parameters with one patient 
reassigned a diagnosis of AMI. However, this may not be 
the case for other clinical studies [5]. Roche Diagnostics 
has implemented more stringent criteria in the quality 
control process, including the use of narrower intervals 
and additional control samples both at and below the clin-
ical decision limit to detect drifts in calibration traceability 
[6]. Laboratories measuring troponin are well advised to 
monitor assay bias and any drifts in calibration traceability 
across different reagent lots by using not only the manu-
facturer’s quality controls but also a patient pool with a 
concentration close to the decision limit for troponin [7].
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors 
stated that there are no conflicts of interest regarding the 
publication of this article. Research funding played no 
role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in 
the decision to submit the report for publication. JRT, JPJU 
have no conflicts of interest.
Research funding: WAP: Queensland Emergency Medicine 
Research Foundation, Abbott, Roche, Alere, Beckman 
Coulter; LC: Queensland Emergency Medical Research 
Foundation, Abbott, Roche, Alere, Siemens, Radiometer 
Pacific; JHG: Queensland Emergency Medical Research 
Foundation, Roche, Siemens; AFTB: Queensland Emer-
gency Medical Research Foundation.
Employment or leadership: None declared.
Honorarium: WAP: Abbott, Astra Zeneca, Hospira, Sanofi 
Aventis; LC: Alere, Boehringer Ingelhiem, Pfizer,  Astra 
Zeneca, Abbott, Radiometer Pacific; AFTB: Astra Zeneca, 
Boehringer Ingelheim, Aventis, Roche; CJH: Abbott, 
Astra, Bayer, Boehringer, Boston Scientific, Cordis, Lilly, 
Medtronic, Pfizer, Sanofi, Schering-Plough.
Received July 1, 2013; accepted July 12, 2013; previously published 
online August 8, 2013
References
1. Apple FS, Jaffe AS. Clinical implications of a recent adjustment 
to the high-sensitivity cardiac troponin T assay: user beware 
[letter]. Clin Chem 2012;58:1599–600.
2. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, 
et al. 2-hour accelerated diagnostic protocol to assess patients 
with chest pain symptoms using contemporary troponins 
0
10
20
30
40
50
60
70
80
5 10 15 20 25 30 35 40 45 50 55
Recalculated hs-TnT, ng/L
%
 D
iff
er
en
ce
, r
ec
al
cu
la
te
d-
or
ig
in
al
 h
s-
Tn
T
Figure 1 Percent difference between recalculated and original 
hs-TnT values after a mathematical recalibration of measured cTnT 
values.
Dotted line indicates +38% bias at the decision limit of 14 ng/L 
cTnT.
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